Eli Lilly "peer perform"

03/31/06 - Bear Stearns

NEW YORK, March 31 (newratings.com) - Analyst John Boris of Bear Stearns reiterates his "peer perform" rating on Eli Lilly & Co (LLY).

In a research note published this morning, the analyst mentions that the company is likely to post its EPS for the current year at $3.15, as compared to the consensus of $3.13. The analyst expects the Zyprexa brand to stabilise in the US going forward on account of the results from CATIE and a $700 million charge to settle 75% of the 8000 lawsuits related to Zyprexa.